ClinicalTrials.Gov Identifier | Biomarker(s) | Regimen | Phase | Sample Size | Stage | Primary Endpoint | Estimated or Actual Study Period [reference] |
---|---|---|---|---|---|---|---|
NCT05472623 (Neo-Kan) | KRASG12C PD-L1 expression | Adagrasib BID prior to surgery versus Adagrasib BID and IV nivolumab every 2 weeks for 3 doses prior to surgery | II | 42 | IB-IIIA | pCR | November 20, 2022—November 20, 2025 |
NCT04941417 | PD-L1 expression | PD-(L)1 inhibitor with chemotherapy | II | 60 | I (T ≥ 4 cm), IIA, IIB, IIIA, IIIB | MPR | November 24, 2020—June 30, 2023 |
NCT04379739 | PD-L1 expression VEGF | Camrelizumab + platinum-based chemotherapy versus Camrelizumab + Apatinib | II | 82 | II-IIIA | MPR | July 26, 2020—December 30, 2026 |
NCT04875585 (INNWOP1) | PD-L1 expression VEGF | Pembrolizumab + Lenvatinib | II | 33 | IA3-IIIA | MPR | May 2021—December 2027 |
NCT04762030 | PD-L1 expression | Durvalumab + Carboplatin + Nab-paclitaxel + Anlotinib | II | 39 | III | PFS | February 8, 2021—December 30, 2025 |
NCT04832854 | PD-L1 expression | Atezolizumab + Tiragolumab with or without platinum-based chemotherapy | II | 82 | Stage II, IIIA, or select IIIB (T3N2 only) | Surgical delays, complications, surgical cancellations, adverse events, MPR | April 23, 2021—February 28, 2027 |
NCT04846634 (ALTER-L043) | PD-L1 expression VEGFR FGFR PDGFR c-kit | Penpulimab + chemotherapy versus Penpulimab + Anlotinib versus Penpulimab + chemotherapy + Anlotinib | II | 90 | IIB-IIIB (N2) | MPR | August 2021—February 2028 |
NCT04512430 | PD-L1 expression VEGF | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed | II | 26 | IIIA | MPR | December 2, 2020—August 2026 |
NCT04506242 | PD-L1 expression VEGF | Apatinib + neoadjuvant/adjuvant Camrelizumab | II | 74 | IIA-IIIB | MPR | September 15, 2020—December 30, 2025 |
NCT04123379 | PD-L1 expression | Nivolumab + CCR2/5-inhibitor or anti-IL-8 (NSCLC cohort) | II | 50 | Not specified | MPR, STN | March 19, 2020—October 2024 |
NCT04040361 (EAST ENERGY) | PD-L1 expression VEGF | Pembrolizumab + Ramucirumab | II | 24 | IB-IIIA | MPR | November 30, 2019—November 30, 2025 |
NCT04205552 (NEOpredict) | PD-L1 expression LAG-3 | Nivolumab + Relatlimab | II | 60 | I, II, IIIA | Feasibility | March 4, 2020 – June 2024 |
NCT03872661 | PD-L1 expression VEGF | Sintilimab + Bevacizumab + Pemetrexed + Carboplatin | II | 36 | III | Resectibility rate | March 1, 2019—March 1, 2024 |
NCT03968419 (CANOPY-N) | PD-L1 expression IL-1β | Pembrolizumab ± Canakinumab or Pembrolizumab monotherapy | II | 110 | IB-IIIA | MPR | November 5, 2019—March 21, 2023 |
NCT04758949 | PD-L1 expression IL-1ß | Nivolumab ± FL-101 | II | 90 | IA3, IB, II, or IIIA | Adverse events | July 1, 2021—February 1, 2023 |
NCT04133337 | PD-L1 expression VEGF | SHR-1210 (PD-1 Antibody) + Apatinib | I/II | 20 | IB-IIIA | MPR | November 1, 2019—June 2021 |